![Jaakko Lappalainen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jaakko Lappalainen is a former Executive Director of Drug Development Services at Premier Research Group Ltd., former Vice President of Clinical Development at Marinus Pharmaceuticals, Inc., former Senior Vice President of Clinical Development and Pharmacovigilance at VistaGen Therapeutics, Inc. from 2021 to 2023, and a former Assistant Professor at Yale School of Medicine.
| Företag | Position | Slut |
|---|---|---|
| VISTAGEN THERAPEUTICS, INC. | Företagsledare/Principal | 2023-06-01 |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
Premier Research Group Ltd.
 Premier Research Group Ltd. Miscellaneous Commercial ServicesCommercial Services Provides contract research services to pharmaceutical industry | Företagsledare/Principal | - |
| MARINUS PHARMACEUTICALS, INC. | Teknisk/Vetenskaplig/F&U Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
| Privata företag | 4 |
|---|---|
Premier Research Group Ltd.
Premier Research Group Ltd. Miscellaneous Commercial ServicesCommercial Services Provides contract research services to pharmaceutical industry | Commercial Services |
Marinus Pharmaceuticals, Inc.
 Marinus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for rare genetic epilepsies and other seizure disorders | Health Technology |
VistaGen Therapeutics, Inc.
 VistaGen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops central nervous system therapies | Health Technology |
Yale School of Medicine
Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Välj din utgåva
All finansiell information anpassad till den nationella nivån
